InMed Pharmaceuticals Inc近日通过提交给美国证券交易委员会(SEC)的文件,公布了其阿尔茨海默病治疗项目INM-901的积极研究数据。这一进展为该公司在神经退行性疾病领域的研发工作提供了重要支持。
InMed Pharmaceuticals Inc近日通过提交给美国证券交易委员会(SEC)的文件,公布了其阿尔茨海默病治疗项目INM-901的积极研究数据。这一进展为该公司在神经退行性疾病领域的研发工作提供了重要支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.